M2R
0.003
50%
CNJ
0.02
-73.7%
RAD
0.026
44.4%
NAE
0.002
-33.3%
MEM
0.004
33.3%
SPX
0.002
-33.3%
VKA
0.009
28.6%
RKB
0.003
-25%
RDN
0.005
25%
TAR
0.018
-25%
DRO
2.83
23%
OEL
0.004
-20%
NFM
0.017
21.4%
TDO
0.14
-17.6%
4DX
2.95
20.9%
BMO
0.033
-15.4%
VAR
0.006
20%
AX8
0.006
-14.3%
PTX
0.11
18.3%
BNL
0.006
-14.3%
BLU
0.007
16.7%
ECS
0.006
-14.3%
GLL
0.007
16.7%
ENV
0.006
-14.3%
MGL
0.245
16.7%
SER
0.006
-14.3%
VSR
0.035
16.7%
AZY
0.537
-13.4%
EOS
7.44
15.2%
ALM
0.007
-12.5%
BKB
0.8
15.1%
MML
0.028
-12.5%
SNX
0.031
14.8%
PL9
0.007
-12.5%
HPG
1.385
14.5%
SRJ
0.014
-12.5%
CLX
2.15
13.2%
GG1
0.185
-11.9%
MQR
0.009
12.5%
D3E
0.305
-11.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PharmAust Limited (ASX:PAA): Developing new treatments for neurodegenerative diseases

Ahead of appearing at the Spark+ Australian Equities Day in Singapore, PharmAust’s (ASX:PAA) Managing Director Dr Michael Thurn speaks with The Stock Network’s Lel Smits about:

🧬 A re-prioritised commercialisation strategy: PharmAust focus on neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s disease
🧬 Monepantel gets US FDA Orphan Drug Designation for treatment of ALS:
Next steps following PharmAust’s Monepantel recently granted Orphan Drug Designation for the treatment of ALS by the US FDA

Watch the full interview ⚡️ https://youtu.be/VJkvSG3bkrA
Register to attend Australian Equities Day: https://www.eventbrite.sg/e/spark-plus-australian-equities-day-tickets-939180011697